Immune Checkpoint Inhibitors: all 7,569 studies that test it

Page 46 of 76. Open to participants first (2,567), then studies with results posted, then the rest; newest registration first within each.

• Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and ChemoradiationActive, not recruitingNCT05975307Phase 2
• Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of GlioblastomaWithdrawnNCT05973903Phase 1/2
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACActive, not recruitingNCT05968326Phase 2
• The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon CancerActive, not recruitingNCT05961709Phase 2
• A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy ParticipantsCompletedNCT05959109Phase 1
• A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7SuspendedNCT05958199Phase 1
• Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After TreatmentActive, not recruitingNCT05957510Phase 2
• A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05949606Phase 1/2
• BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsActive, not recruitingNCT05943106Phase 3
• Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II TrialStatus unknownNCT05942573Phase 2
• A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid TumorsStatus unknownNCT05942378Phase 1
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2
• Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJCompletedNCT05941481Phase 2
• A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue SarcomaSuspendedNCT05941325Phase 2
• OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung CancerWithdrawnNCT05935774Phase 2
• AK104 for Recurrent or Metastatic Vulvar CancerTerminatedNCT05932212Phase 2
• Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before SurgerySuspendedNCT05929664Phase 2
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialSuspendedNCT05928806Phase 2
• Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy EfficacyActive, not recruitingNCT05927142Phase 1/2
• A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2
• Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Active, not recruitingNCT05925530Phase 2
• A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)CompletedNCT05924880Phase 3
• PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaActive, not recruitingNCT05922904Phase 2
• Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerActive, not recruitingNCT05920798Phase 1/2
• Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal JunctionStatus unknownNCT05918419Phase 2
• A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBCActive, not recruitingNCT05918133Phase 1/2
• A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPMCompletedNCT05918107Phase 2
• Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic CholangiocarcinomaStatus unknownNCT05913661Phase 2
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active, not recruitingNCT05911295Phase 3
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 1
• A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05908734Phase 1/2
• A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaCompletedNCT05907122Phase 3
• A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Phase 3
• AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05904379Phase 1/2
• Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)WithdrawnNCT05900648Phase 2
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsActive, not recruitingNCT05899608Phase 3
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyActive, not recruitingNCT05899049Phase 3
• Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerWithdrawnNCT05898828Phase 1/2
• TEIPP Immunotherapy in Patients With NSCLCCompletedNCT05898763Phase 1/2
• Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLCActive, not recruitingNCT05894889Phase 2
• Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial CancersWithdrawnNCT05894447Phase 1
• A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT05888844Phase 2
• Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLCActive, not recruitingNCT05888402Phase 2
• A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaActive, not recruitingNCT05886634Phase 2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TWithdrawnNCT05886257Phase 2
• Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05883644Phase 3
• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2
• Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung CancerActive, not recruitingNCT05882513Phase 2
• PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal CancerCompletedNCT05880082Phase 2
• A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingNCT05879978Phase 1
• A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
• Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent GlioblastomaWithdrawnNCT05879120Phase 2
• A Study of PM8002 in Combination With Chemotherapy in Patients With SCLCActive, not recruitingNCT05879068Phase 2
• A Study of PM8002 in Combination With Chemotherapy in Patients With NENActive, not recruitingNCT05879055Phase 2
• A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.Active, not recruitingNCT05878691Phase 1
• Deep sequencIng in Cutaneous Squamous CEll caRciNomasActive, not recruitingNCT05878288Phase 2
• A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCCCompletedNCT05877820Phase 2
• The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver MetastasesStatus unknownNCT05877001Phase 2
• Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous CarcinomaActive, not recruitingNCT05870761Phase 2
• Study of ZGGS15 in Patients With Advanced Solid TumorsCompletedNCT05864573Phase 1
• Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingNCT05864534Phase 2
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsCompletedNCT05864144Phase 1/2
• PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Phase 2
• A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced MalignanciesTerminatedNCT05861947Phase 1
• Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsCompletedNCT05858736Phase 1
• Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)Active, not recruitingNCT05856695Phase 2
• A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05852691Phase 2
• The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)TerminatedNCT05849246Phase 2
• A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C MutationsWithdrawnNCT05848843Phase 1
• A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT05848011Phase 2
• A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal CancerActive, not recruitingNCT05846867Phase 1/2
• Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi SarcomaWithdrawnNCT05846724Phase 2
• A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT05846516Phase 1
• A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)Active, not recruitingNCT05845814Phase 1/2
• Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After SurgeryStatus unknownNCT05844371Phase 2
• A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCActive, not recruitingNCT05844150Phase 2
• Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung CancerWithdrawnNCT05840770Phase 2
• AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05840016Phase 3
• Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal CancerStatus unknownNCT05839470Phase 2
• Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) CancerActive, not recruitingNCT05836584Phase 2
• Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaTerminatedNCT05834543Phase 1/2
• NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKingActive, not recruitingNCT05825625Phase 2
• A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid TumorsCompletedNCT05824663Phase 1
• Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial CancerActive, not recruitingNCT05824481Phase 2
• Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical CancerActive, not recruitingNCT05824468Phase 2
• Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial CarcinomaStatus unknownNCT05823246Phase 2
• Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05822752Phase 2
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid TumorsTerminatedNCT05821777Phase 1/2
• Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.Status unknownNCT05821192Not applicable
• Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05816499Phase 1/2
• Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT05813626Phase 2
• Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast CancerWithdrawnNCT05809895Phase 2
• A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell CarcinomaActive, not recruitingNCT05808608Phase 1/2
• Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.CompletedNCT05807776Phase 2
• Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCCCompletedNCT05807542Phase 2
• NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHNCompletedNCT05802290Phase 3
• Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal MetastasisActive, not recruitingNCT05802056Phase 1
• A Phase I Study of QL1604 for Advanced Solid TumorsStatus unknownNCT05801094Phase 1
• A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerActive, not recruitingNCT05800015Phase 2/3
• Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal CancerStatus unknownNCT05799443Phase 2

← Immune Checkpoint Inhibitors overview